Symbol="SYRS"
AssetType="Common Stock"
Name="Syros Pharmaceuticals Inc"
Description="Syros Pharmaceuticals, Inc., a biopharmaceutical company, is focused on developing treatments for cancer and monogenic diseases and building a line of gene control drugs. The company is headquartered in Cambridge, Massachusetts."
CIK="1556263"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="75174000"
EBITDA="-139508000"
PERatio="None"
PEGRatio="0"
BookValue="5.23"
DividendPerShare="0"
DividendYield="0"
EPS="-4.38"
RevenuePerShareTTM="0.686"
ProfitMargin="0"
OperatingMarginTTM="-11.52"
ReturnOnAssetsTTM="-0.498"
ReturnOnEquityTTM="-1.101"
RevenueTTM="12367000"
GrossProfitTTM="14880000"
DilutedEPSTTM="-4.38"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.46"
AnalystTargetPrice="26.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="2.99"
PriceToBookRatio="0.579"
EVToRevenue="2.578"
EVToEBITDA="0.99"
Beta="1.612"
num_52WeekHigh="10.5"
num_52WeekLow="2.42"
num_50DayMovingAverage="3.416"
num_200DayMovingAverage="3.635"
SharesOutstanding="20595500"
DividendDate="None"
ExDividendDate="None"
symbol="SYRS"
open="3.92"
high="3.95"
low="3.57"
price="3.65"
volume="47337.00"
latest_trading_day="2023-08-04"
previous_close="3.88"
change="-0.23"
change_percent="-5.9278%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="57"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="43"
Volume_recent_avg="84113"
Change_recent_avg="0.01"
Delta_recent_avg="0.19"
Variance_recent_avg="0.09"
Change_ratio_recent_avg="-0.11"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="43"
Aroon_momentum_negative="57"
image_negative_thumbnail_id_1="147"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0029.jpeg"
image_negative_thumbnail_id_2="172"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0004.jpeg"
image_neutral_thumbnail_id_1="566"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0033.jpeg"
image_neutral_thumbnail_id_2="540"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0059.jpeg"
image_positive_thumbnail_id_1="693"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0015.jpeg"
image_positive_thumbnail_id_2="1007"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0169.jpeg"
image_professor_thumbnail_id_1="1187"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0021.jpeg"
image_professor_thumbnail_id_2="1201"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0035.jpeg"
